Yu‐Feng Wei

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2019 · 201 citations · Full text

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu et al. · The Lancet Respiratory Medicine · 2023 · 137 citations

Tobacco Control, Family Medicine, Cancer Epidemiology +10

Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease

Chih-Hao Chang, Li‐Pang Chuang, Shih‐Wei Lin et al. · BMC Pulmonary Medicine · 2016 · 60 citations · Full text

The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study

Meng‐Jer Hsieh, Shu‐Yi Huang, Tsung‐Ming Yang et al. · International Journal of COPD · 2018 · 60 citations · Full text